Rafael Holdings, Inc. (RFL)

NYSE: RFL · IEX Real-Time Price · USD
1.96
0.14 (7.69%)
At close: May 27, 2022 4:00 PM
2.00
0.04 (2.04%)
After-hours:May 27, 2022 7:32 PM EDT
Market Cap42.12M
Revenue (ttm)4.10M
Net Income (ttm)-129.28M
Shares Out21.49M
EPS (ttm)-7.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume63,501
Open1.87
Previous Close1.82
Day's Range1.85 - 2.00
52-Week Range1.60 - 66.44
Beta1.98
Analystsn/a
Price Targetn/a
Earnings DateJun 13, 2022

About RFL

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated ...

IndustryReal Estate Management & Development
Employees51
Stock ExchangeNYSE
Ticker SymbolRFL
Full Company Profile

Financial Performance

In 2021, RFL's revenue was $3.97 million, a decrease of -19.12% compared to the previous year's $4.91 million. Losses were -$24.54 million, 135.7% more than in 2020.

Financial Statements

News

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Tr...

Cranbury, NJ, May 24, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceutic...

3 days ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL

NEW YORK , March 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL).  Such investors are advised to co...

2 months ago - PRNewsWire

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

NEWARK, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for the t...

2 months ago - GlobeNewsWire

The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Rafael Holdings, Inc. (“Rafael” or the “Company”) (NYSE: RFL) on behalf of investors concerning the Company'...

2 months ago - Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Rafael Holdings, Inc...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Rafael Holdings, Inc. (“Rafael” or the “Compan...

2 months ago - Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf o...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Rafael Holdings, Inc. (“Rafael” or the “Company”) (NYSE: RFL) investors concerning the Company's p...

2 months ago - Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rafael Holdings, Inc. (R...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Rafael Holdings, In...

2 months ago - Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of In...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Rafael Holdings, Inc. (“Rafael” or the “Company”) (NYSE: RFL) investors concerning the Company's po...

2 months ago - Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Rafael Holdings, Inc. (“Rafael” or the “Company”) (NYSE: RFL) on behalf of investors concerning the Company's...

2 months ago - Business Wire

William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022

NEWARK, N.J., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), a company focused on discovering and developing novel cancer and immune metabolism therapeuties through its Barer Inst...

4 months ago - GlobeNewsWire

Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical T...

CRANBURY, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, today announce...

4 months ago - GlobeNewsWire

Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in Fir...

Company Will Open Additional Sites and Has Begun Enrolling Patients in the Second Cohort of the Trial Company Will Open Additional Sites and Has Begun Enrolling Patients in the Second Cohort of the Trial

4 months ago - GlobeNewsWire

Rafael Holdings Reports First Quarter Fiscal 2022 Financial and Operating Results

NEWARK, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), an early-stage cancer and immune metabolism therapeutics company, today reported its financial results for the first q...

5 months ago - GlobeNewsWire

Rafael Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) From Phase 2 Clinical Trial for Refractory B...

Published Study Titled, “Complete Remission with Devimistat (CPI-613) in Refractory Burkitt Lymphoma” Published Study Titled, “Complete Remission with Devimistat (CPI-613) in Refractory Burkitt Lymphoma”

5 months ago - GlobeNewsWire

Rafael Holdings Realigns Leadership Team to Support Earlier Stage Pipeline Focus

- Ameet Mallik to Transition CEO Role to Chairman, Howard Jonas, and Will Remain a Highly Engaged Member of the Company's Board of Directors and Chair Newly Established Transition Committee -

6 months ago - GlobeNewsWire

Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimista...

New Trial Sites Open at Cleveland Clinic Children's and University of Michigan New Trial Sites Open at Cleveland Clinic Children's and University of Michigan

6 months ago - GlobeNewsWire

European Medicines Agency Grants Orphan Drug Designation to Rafael Pharmaceuticals' CPI-613® (Devimistat) for Treatme...

CRANBURY, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, today announce...

6 months ago - GlobeNewsWire

Here's Why Rafael Holdings Is Plummeting Today

A clinical trial failure with the company's lead candidate has investors running for the exits.

6 months ago - The Motley Fool

Rafael Holdings stock plummets after cancer-treatment trial missed primary endpoint

Shares of Rafael Holdings Inc. RFL, -80.12% plummeted 78% in active premarket trading Thursday, to pace all premarket decliners, after the developer of cancer treatments said a Phase 3 trial of CPI-613 ...

6 months ago - Market Watch

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation into the Fairness of the Merger of Raf...

New York, New York--(Newsfile Corp. - October 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rafael Holdings, Inc. ("Rafael Holdin...

7 months ago - Newsfile Corp

Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08

NEWARK, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), announced that today it made a grant to Dr. Mary Margaret Huizinga of options to purchase 122,341 shares of Class B co...

7 months ago - GlobeNewsWire

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2021 Financial and Operating Results and Provides Busines...

We expect Rafael Pharmaceuticals to report top line data from its AVENGER 500 Phase 3 registrational clinical trial in metastatic pancreatic cancer this calendar year

7 months ago - GlobeNewsWire

Rafael Holdings Appoints Mimi Huizinga, MD, MPH as Chief Development and Medical Officer

NEWARK, N.J., Oct. 6, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute and...

7 months ago - PRNewsWire

Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (devimistat) in Combination with Hyd...

CRANBURY, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced that the Pha...

8 months ago - GlobeNewsWire

Rafael Holdings Continues to Expand its Management Team with a Highly Experienced Global Biopharmaceutical Executive ...

NEWARK, N.J., Sept. 24, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute a...

8 months ago - PRNewsWire